Loading...
XWARSPH
Market cap364mUSD
Dec 20, Last price  
12.25PLN
1D
-3.92%
1Q
-3.16%
Name

Sopharma AD

Chart & Performance

D1W1MN
XWAR:SPH chart
P/E
7.10
P/S
0.36
EPS
0.79
Div Yield, %
4.84%
Shrs. gr., 5y
-0.28%
Rev. gr., 5y
9.71%
Revenues
1.89b
+13.53%
644,731,000688,579,000762,689,000840,517,000874,984,000877,085,0001,017,105,0001,179,143,0001,281,587,0001,438,826,0001,603,310,0001,662,992,0001,887,947,000
Net income
95m
+33.87%
38,404,00035,196,00029,248,00020,178,00021,314,00050,638,00039,998,00028,343,00086,994,00029,805,00089,496,00071,121,00095,207,000
CFO
45m
-63.86%
38,404,00035,196,00029,248,00020,178,00021,314,00050,638,00039,998,00028,343,000-128,443,999-179,411,000-75,963,000124,622,00045,033,000
Dividend
Jul 11, 20240.19638 PLN/sh
Earnings
Jun 30, 2025

Profile

Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company's products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of functions of the sexual system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions. It also trades in food supplements; provides secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; and purchases, collects, grows, produces, and trades in herbs and medicinal plants. In addition, the company engages in the retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers market and public opinion research services; and engages in non-pharma activities, such as veterinary vaccines, infusion solutions. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
IPO date
Jan 20, 1998
Employees
4,770
Domiciled in
BG
Incorporated in
BG

Valuation

Title
BGN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,887,947
13.53%
1,662,992
3.72%
1,603,310
11.43%
Cost of revenue
1,727,791
1,358,099
1,320,151
Unusual Expense (Income)
NOPBT
160,156
304,893
283,159
NOPBT Margin
8.48%
18.33%
17.66%
Operating Taxes
11,821
9,153
5,871
Tax Rate
7.38%
3.00%
2.07%
NOPAT
148,335
295,740
277,288
Net income
95,207
33.87%
71,121
-20.53%
89,496
200.27%
Dividends
(71,889)
(11)
(63)
Dividend yield
Proceeds from repurchase of equity
150,041
(1,840)
(4,116)
BB yield
Debt
Debt current
223,638
169,295
238,442
Long-term debt
181,123
192,904
136,850
Deferred revenue
6,155
6,783
Other long-term liabilities
39,116
19,381
22,876
Net debt
40,465
174,923
204,517
Cash flow
Cash from operating activities
45,033
124,622
(75,963)
CAPEX
(24,390)
(23,219)
(27,110)
Cash from investing activities
(62,849)
(63,171)
(68,065)
Cash from financing activities
126,845
(64,342)
156,606
FCF
216,418
304,058
309,544
Balance
Cash
128,791
19,654
37,677
Long term investments
235,505
167,622
133,098
Excess cash
269,899
104,126
90,610
Stockholders' equity
810,285
702,955
645,555
Invested Capital
855,921
910,086
913,408
ROIC
16.80%
32.44%
29.65%
ROCE
14.23%
29.89%
27.97%
EV
Common stock shares outstanding
140,196
121,494
125,368
Price
Market cap
EV
EBITDA
212,229
356,961
333,778
EV/EBITDA
Interest
10,213
6,009
10,791
Interest/NOPBT
6.38%
1.97%
3.81%